| Trial ID: | L5155 |
| Source ID: | NCT01334203
|
| Associated Drug: |
Ranolazine
|
| Title: |
A Study on the Effects of Ranolazine on Exercise Duration in Subjects With Chronic Stable Angina and Coronary Artery Disease (CAD) With Type 2 Diabetes Mellitus (T2DM)
|
| Acronym: |
|
| Status: |
WITHDRAWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Angina Pectoris|Coronary Artery Disease|Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Ranolazine
|
| Outcome Measures: |
Primary: The primary efficacy endpoint is the change from baseline in exercise treadmill duration in the peak ETT at week 12 or last visit., 12 weeks | Secondary: Time to onset of angina during peak ETT at week 12 or last visit, 12 weeks|Time to onset of 1 mm ST-segment depression during peak ETT at week 12 or last visit, 12 weeks|Change from baseline in exercise treadmill duration in the trough ETT at week 12, 12 weeks
|
| Sponsor/Collaborators: |
Sponsor: Gilead Sciences
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
0
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2011-05
|
| Completion Date: |
2012-12
|
| Results First Posted: |
|
| Last Update Posted: |
2012-07-31
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT01334203
|
